Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

Biomarkers in Type 2 diabetes: improving risk stratification with the PreDx ® Diabetes Risk Score.

Kolberg JA, Gerwien RW, Watkins SM, Wuestehube LJ, Urdea M.

Expert Rev Mol Diagn. 2011 Nov;11(8):775-92. doi: 10.1586/erm.11.63.

PMID:
22022939
2.

Microfluidic strategies applied to biomarker discovery and validation for multivariate diagnostics.

Tarasow TM, Penny L, Patwardhan A, Hamren S, McKenna MP, Urdea MS.

Bioanalysis. 2011 Oct;3(19):2233-51. doi: 10.4155/bio.11.224. Review.

PMID:
21985417
3.

Saliva, diagnostics, and dentistry.

Urdea MS, Neuwald PD, Greenberg BL, Glick M, Galloway J, Williams D, Wong DT.

Adv Dent Res. 2011 Oct;23(4):353-9. doi: 10.1177/0022034511420432.

PMID:
21917745
4.

Validation of a multimarker model for assessing risk of type 2 diabetes from a five-year prospective study of 6784 Danish people (Inter99).

Urdea M, Kolberg J, Wilber J, Gerwien R, Moler E, Rowe M, Jorgensen P, Hansen T, Pedersen O, Jørgensen T, Borch-Johnsen K.

J Diabetes Sci Technol. 2009 Jul 1;3(4):748-55.

5.

Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort.

Kolberg JA, Jørgensen T, Gerwien RW, Hamren S, McKenna MP, Moler E, Rowe MW, Urdea MS, Xu XM, Hansen T, Pedersen O, Borch-Johnsen K.

Diabetes Care. 2009 Jul;32(7):1207-12. doi: 10.2337/dc08-1935.

6.

Requirements for high impact diagnostics in the developing world.

Urdea M, Penny LA, Olmsted SS, Giovanni MY, Kaspar P, Shepherd A, Wilson P, Dahl CA, Buchsbaum S, Moeller G, Hay Burgess DC.

Nature. 2006 Nov 23;444 Suppl 1:73-9. No abstract available.

PMID:
17159896
7.

ProbeDesigner: for the design of probesets for branched DNA (bDNA) signal amplification assays.

Bushnell S, Budde J, Catino T, Cole J, Derti A, Kelso R, Collins ML, Molino G, Sheridan P, Monahan J, Urdea M.

Bioinformatics. 1999 May;15(5):348-55.

PMID:
10366654
8.

Quantification of HCV RNA in Liver Tissue by bDNA Assay.

Dailey PJ, Collins ML, Urdea MS, Wilber JC.

Methods Mol Med. 1999;19:119-29. doi: 10.1385/0-89603-521-2:119.

PMID:
21374354
9.

Quantification of HCV RNA in Clinical Specimens by Branched DNA (bDNA) Technology.

Wilber JC, Urdea MS.

Methods Mol Med. 1999;19:71-8. doi: 10.1385/0-89603-521-2:71.

PMID:
21374350
10.

Quantification of cytokine mRNA in peripheral blood mononuclear cells using branched DNA (bDNA) technology.

Shen LP, Sheridan P, Cao WW, Dailey PJ, Salazar-Gonzalez JF, Breen EC, Fahey JL, Urdea MS, Kolberg JA.

J Immunol Methods. 1998 Jun 1;215(1-2):123-34.

PMID:
9744754
11.

Direct quantitation of HIV by flow cytometry using branched DNA signal amplification.

Van Cleve M, Ostrerova N, Tietgen K, Cao W, Chang C, Collins ML, Kolberg J, Urdea M, Lohman K.

Mol Cell Probes. 1998 Aug;12(4):243-7.

PMID:
9727202
12.

Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy.

Eastman PS, Mittler J, Kelso R, Gee C, Boyer E, Kolberg J, Urdea M, Leonard JM, Norbeck DW, Mo H, Markowitz M.

J Virol. 1998 Jun;72(6):5154-64.

13.

Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection.

Nelson DR, Lim HL, Marousis CG, Fang JW, Davis GL, Shen L, Urdea MS, Kolberg JA, Lau JY.

Dig Dis Sci. 1997 Dec;42(12):2487-94.

PMID:
9440625
15.
16.

Hepatitis C--diagnosis and monitoring.

Urdea MS, Wuestehube LJ, Laurenson PM, Wilber JC.

Clin Chem. 1997 Aug;43(8 Pt 2):1507-11. Review.

17.

Effect of interferon-alpha and ribavirin therapy on serum GB virus C/hepatitis G virus (GBV-C/HGV) RNA levels in patients chronically infected with hepatitis C virus and GBV-C/HGV.

Lau JY, Qian K, Detmer J, Collins ML, Orito E, Kolberg JA, Urdea MS, Mizokami M, Davis GL.

J Infect Dis. 1997 Aug;176(2):421-6.

PMID:
9237707
18.

A branched DNA signal amplification assay for quantification of nucleic acid targets below 100 molecules/ml.

Collins ML, Irvine B, Tyner D, Fine E, Zayati C, Chang C, Horn T, Ahle D, Detmer J, Shen LP, Kolberg J, Bushnell S, Urdea MS, Ho DD.

Nucleic Acids Res. 1997 Aug 1;25(15):2979-84.

19.

Circulating CD8 T cells show increased interferon-gamma mRNA expression in HIV infection.

Breen EC, Salazar-Gonzalez JF, Shen LP, Kolberg JA, Urdea MS, Martinéz-Maza O, Fahey JL.

Cell Immunol. 1997 May 25;178(1):91-8.

PMID:
9184702
20.

Detection of GB virus-C/hepatitis G virus RNA in serum by reverse transcription polymerase chain reaction.

Bhardwaj B, Qian K, Detmer J, Mizokami M, Kolberg JA, Urdea MS, Schlauder G, Linnen JM, Kim JP, Davis GL, Lau JY.

J Med Virol. 1997 May;52(1):92-6.

PMID:
9131464
21.

Regulation of insulin preRNA splicing by glucose.

Wang J, Shen L, Najafi H, Kolberg J, Matschinsky FM, Urdea M, German M.

Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4360-5.

22.

Hepatitis C virus: quantitation and distribution in liver.

Terrault NA, Dailey PJ, Ferrell L, Collins ML, Wilber JC, Urdea MS, Bhandari BN, Wright TL.

J Med Virol. 1997 Mar;51(3):217-24.

PMID:
9139087
23.

An enhanced-sensitivity branched-DNA assay for quantification of human immunodeficiency virus type 1 RNA in plasma.

Kern D, Collins M, Fultz T, Detmer J, Hamren S, Peterkin JJ, Sheridan P, Urdea M, White R, Yeghiazarian T, Todd J.

J Clin Microbiol. 1996 Dec;34(12):3196-202.

24.

Correlation between serum HCV RNA and aminotransferase levels in patients with chronic HCV infection.

Ghany MG, Chan TM, Sanchez-Pescador R, Urdea M, Lok AS.

Dig Dis Sci. 1996 Nov;41(11):2213-8.

25.

HCV viraemia is more important than genotype as a predictor of response to interferon in Sicily (southern Italy).

Magrin S, Craxi A, Fabiano C, Marino L, Fiorentino G, Lo Iacono O, Volpes R, Di Marco V, Almasio P, Vaccaro A, Urdea MS, Wilber JC, Bonura C, Gianguzza F, Capursi V, Filiberti S, Stuyver L, Pagliaro L.

J Hepatol. 1996 Nov;25(5):583-90.

PMID:
8938531
26.

Detection of Trypanosoma brucei spp. in human blood by a nonradioactive branched DNA-based technique.

Harris E, Detmer J, Dungan J, Doua F, White T, Kolberg JA, Urdea MS, Agabian N.

J Clin Microbiol. 1996 Oct;34(10):2401-7.

27.

Hepatitis C virus RNA quantification in right and left lobes of the liver in patients with chronic hepatitis C.

Idrovo V, Dailey PJ, Jeffers LJ, Coelho-Little E, Bernstein D, Bartholomew M, Alvarez L, Urdea MS, Collins ML, Schiff ER.

J Viral Hepat. 1996 Sep;3(5):239-46.

PMID:
8914003
28.

Quantitation of hepatitis C virus RNA.

Wilber JC, Urdea MS.

Ann Intern Med. 1996 Jul 15;125(2):155-6. No abstract available.

PMID:
8678378
29.

Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes by using branched-DNA technology.

Detmer J, Lagier R, Flynn J, Zayati C, Kolberg J, Collins M, Urdea M, Sánchez-Pescador R.

J Clin Microbiol. 1996 Apr;34(4):901-7.

30.

Levels of hepatitis C virus in blood donors infected with different viral genotypes. International HCV Collaborative Study Group.

Smith DB, Davidson F, Yap P, Brown H, Kolberg J, Detmer J, Urdea M, Simmonds P, International HCV Collaborati.

J Infect Dis. 1996 Mar;173(3):727-30.

PMID:
8627040
31.

Significance of hepatic expression of hepatitis C viral antigens in chronic hepatitis C.

González-Peralta RP, Fang JW, Davis GL, Gish RG, Kohara M, Mondelli MU, Urdea MS, Mizokami M, Lau JY.

Dig Dis Sci. 1995 Dec;40(12):2595-601.

PMID:
8536518
32.

Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level.

Yamada G, Takatani M, Kishi F, Takahashi M, Doi T, Tsuji T, Shin S, Tanno M, Urdea MS, Kolberg JA.

Hepatology. 1995 Nov;22(5):1351-4.

PMID:
7590646
33.

Quantitation of HBV DNA in human serum using a branched DNA (bDNA) signal amplification assay.

Hendricks DA, Stowe BJ, Hoo BS, Kolberg J, Irvine BD, Neuwald PD, Urdea MS, Perrillo RP.

Am J Clin Pathol. 1995 Nov;104(5):537-46.

PMID:
7572814
34.

Nonisotopic hybridization assay for determination of relative amounts of genotypic human immunodeficiency virus type 1 zidovudine resistance.

Eastman PS, Boyer E, Mole L, Kolberg J, Urdea M, Holodniy M.

J Clin Microbiol. 1995 Oct;33(10):2777-80.

35.

Implications of variations of "conserved" regions of hepatitis C virus genome.

Lau JY, Simmonds P, Urdea MS.

Lancet. 1995 Aug 12;346(8972):425-6. No abstract available.

PMID:
7623576
36.

Variation of the hepatitis C virus 5' non-coding region: implications for secondary structure, virus detection and typing. The International HCV Collaborative Study Group.

Smith DB, Mellor J, Jarvis LM, Davidson F, Kolberg J, Urdea M, Yap PL, Simmonds P.

J Gen Virol. 1995 Jul;76 ( Pt 7):1749-61.

PMID:
9049380
38.
39.

Relationship between the presence of circulating anti-GOR and hepatitis C viremia/genotype.

Lau JY, Mizokami M, Davis GL, Kolberg JA, Urdea MS, Orito E, Polito A, DiNello R, Quan S.

J Hepatol. 1995 Jun;22(6):707. No abstract available.

PMID:
7560866
40.

Preparation and characterization of RNA standards for use in quantitative branched DNA hybridization assays.

Collins ML, Zayati C, Detmer JJ, Daly B, Kolberg JA, Cha TA, Irvine BD, Tucker J, Urdea MS.

Anal Biochem. 1995 Mar 20;226(1):120-9.

PMID:
7785763
41.

Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma.

Cao Y, Ho DD, Todd J, Kokka R, Urdea M, Lifson JD, Piatak M Jr, Chen S, Hahn BH, Saag MS, et al.

AIDS Res Hum Retroviruses. 1995 Mar;11(3):353-61.

PMID:
7786581
42.

Prospects for prophylactic and therapeutic hepatitis C virus vaccines.

Houghton M, Choo QL, Kuo G, Weiner A, Chien D, Ralston R, Urdea M, Moss B, Purcell R, Cummins L, et al.

Princess Takamatsu Symp. 1995;25:237-43. Review. No abstract available.

PMID:
8875629
43.

Variations of hepatitis C virus NS5B sequence (nucleotides 8261-8566) do not correlate with response to interferon-alpha therapy.

Nelson DR, Gray AH, Kolberg JA, Joh J, Urdea MS, Mizokami M, Davis GL, Lau JY.

J Viral Hepat. 1995;2(6):285-92.

PMID:
8732174
44.

Evaluation of branched DNA signal amplification for the detection of hepatitis C virus RNA.

Alter HJ, Sanchez-Pescador R, Urdea MS, Wilber JC, Lagier RJ, Di Bisceglie AM, Shih JW, Neuwald PD.

J Viral Hepat. 1995;2(3):121-32.

PMID:
7493306
45.

Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma.

Dewar RL, Highbarger HC, Sarmiento MD, Todd JA, Vasudevachari MB, Davey RT Jr, Kovacs JA, Salzman NP, Lane HC, Urdea MS.

J Infect Dis. 1994 Nov;170(5):1172-9.

PMID:
7963710
46.

The course of hepatitis C virus infection after liver transplantation.

Féray C, Gigou M, Samuel D, Paradis V, Wilber J, David MF, Urdea M, Reynes M, Bréchot C, Bismuth H.

Hepatology. 1994 Nov;20(5):1137-43.

PMID:
7927244
47.

Interferon-alpha therapy for hepatitis C virus infection after liver transplantation.

Wright TL, Combs C, Kim M, Ferrell L, Bacchetti P, Ascher N, Roberts J, Wilber J, Sheridan P, Urdea M.

Hepatology. 1994 Oct;20(4 Pt 1):773-9.

PMID:
7927216
48.

Primary structure of the Streptomyces R61 extracellular DD-peptidase. 1. Cloning into Streptomyces lividans and nucleotide sequence of the gene.

Duez C, Piron-Fraipont C, Joris B, Dusart J, Urdea MS, Martial JA, Frère JM, Ghuysen JM.

Eur J Biochem. 1994 Sep 15;224(3):1079. No abstract available.

49.

Levels of hepatitis C virus RNA and liver histology in chronic type C hepatitis.

Gordon SC, Kodali VP, Silverman AL, Dmuchowski CF, Urdea MS, Chan CS, Wilber JC.

Am J Gastroenterol. 1994 Sep;89(9):1458-61.

PMID:
8079919
50.

Branched DNA signal amplification.

Urdea MS.

Biotechnology (N Y). 1994 Sep;12(9):926-8. No abstract available.

PMID:
7765230

Supplemental Content

Support Center